Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Virios Therapeutics Inc (NQ: VIRI )

0.1550 UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Virios Therapeutics Inc

< Previous 1 2 3 4 5 6 7 Next >
Benzinga's Top Ratings Upgrades, Downgrades For September 20, 2022
Upgrades 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
  
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning, investor! It's time to start the day with a breakdown of the biggest pre-market stock movers for Tuesday morning! 
Via InvestorPlace
Virios Therapeutics Shares Tank After Failing Fibromyalgia Study
Via Benzinga
Earnings Scheduled For August 11, 2022
Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million. 
Via Benzinga
Why O2Micro International Is Trading Higher By 7%; Here Are 25 Stocks Moving Premarket
Gainers 
Via Benzinga
Why KnowBe4 Shares Jumped Over 28%; Here Are 79 Biggest Movers From Yesterday
Gainers Ventoux CCM Acquisition Corp. (NASDAQ: VTAQ) shares jumped 54.6% to settle at $7.05 on Monday. 
Via Benzinga
Virios Therapeutics, Inc. Announces Pricing of Public Offering
From Virios Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Reshape Lifesciences (NASDAQ:RSLS) stock increased by 10.1% to $0.39 during Monday's after-market session. The company's market cap stands at $1.3 million. 
Via Benzinga
Virios Therapeutics, Inc. Announces Proposed Public Offering
From Virios Therapeutics, Inc.
Via Business Wire
US Markets Turn Higher As Dow Jumps Over 100 Points
U.S. stocks traded higher in volatile trading toward the end of trading, with the Dow Jones gaining more than 100 points on Monday. 
Via Benzinga
Dow, S&P 500 Drop In Volatile Trading Ahead Of Fed's Rate Decision
U.S. stocks traded lower in volatile trading toward the end of trading, with the Dow Jones dropping around 40 points on Monday. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
  
Via Benzinga
Analyzing Virios Therapeutics's Short Interest
Virios Therapeutics's (NASDAQ:VIRI) short percent of float has risen 6.58% since its last report. The company recently reported that it has 53 thousand shares sold short, which is... 
Via Benzinga
Why Is Virios Therapeutics (VIRI) Stock Down 71% Today?
Virios Therapeutics (VIRI) stock is falling hard on Monday after revealing results from its Phase 2b Study of IMC-1 in Fibromyalgia. 
Via InvestorPlace
Stocks That Hit 52-Week Lows On Monday
  On Monday, 429 stocks made new 52-week lows. 
Via Benzinga
Why Virios Therapeutics Is Trading Lower By Over 71%, Here Are 55 Stocks Moving In Monday's Mid-Day Session
Gainers MicroCloud Hologram Inc. (NASDAQ: HOLO) shares jumped 134.6% to $19.74. 
Via Benzinga
US Stocks Open Lower; Housing Market Index Drops In September
U.S. stocks traded lower this morning, after recording losses in the previous week. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
  
Via Benzinga
Virios Therapeutics Announces Top-Line Results from Phase 2b Study of IMC-1 in Fibromyalgia
From Virios Therapeutics, Inc. (VIRI)
Via Business Wire
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Virios Therapeutics Commences Mid-Stage Long-COVID Study
Virios Therapeutics (Nasdaq: VIRI) has initiated patient dosing in its exploratory Long-COVID trial evaluating IMC-2 (valacyclovir + celecoxib). 
Via Benzinga
Virios Therapeutics’ Announces Dosing of First Patient in IMC-2 Long-COVID Treatment Trial
From Virios Therapeutics, Inc. (VIRI)
Via Business Wire
This Technology Stock Jumped 55% Following Q2 Results; Here Are 96 Biggest Movers From Yesterday
Gainers Eargo, Inc. (NASDAQ: EAR) jumped 77.2% to close at $2.02. The FDA finalized rule enabling access to over-the-counter hearing aids. 
Via Benzinga
Virios Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update
From Virios Therapeutics, Inc.
Via Business Wire
Virios Therapeutics, Inc. to Present at Investor Summit Group’s Q3 Virtual Conference
From Virios Therapeutics, Inc.
Via Business Wire
Virios Therapeutics: The 'Virus Hypothesis' That Stands to Change the Lives of 10M Americans
Via ACN Newswire
Virios Therapeutics: The 'Virus Hypothesis' That Stands to Change the Lives of 10M Americans
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Virios Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on Thursday, August 11, 2022
From Virios Therapeutics, Inc.
Via Business Wire
Virios Therapeutics (Nasdaq: VIRI) Advancing Potential Paradigm Shift in Fibromyalgia Treatment
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.